CFO transition
Precision BioSciences, Inc. CFO transition: Naresh Tanna to succeed Alex Kelly
Precision BioSciences, Inc. reported in a Form 8-K filed July 27, 2026 that Naresh Tanna will succeed Alex Kelly as Chief Financial Officer, effective August 1, 2026.
In the filing's words
In connection with Mr. Kelly’s promotion to Chief Operating Officer, the Board appointed Naresh Tanna, age 45, as Chief Financial Officer of the Company. As Chief Financial Officer, Mr. Tanna will serve as the Company’s principal financial officer.
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | Precision BioSciences, Inc. (DTIL) |
|---|---|
| Event | Transition |
| Incoming | Naresh Tanna |
| Outgoing | Alex Kelly |
| Title in the filing | Chief Financial Officer |
| Effective | August 1, 2026 |
| 8-K filed | July 27, 2026 |
| Internal promotion | Yes |
| Prior role (per filing) | Vice President of Investor Relations and Chief of Staff to the Chief Executive Officer, Precision BioSciences, Inc. |
| SEC CIK | 0001357874 |
Precision BioSciences, Inc. reported this change in a Form 8-K, Item 5.02, filed July 27, 2026. The filing's own words are quoted above.
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-09-26
Something wrong about Naresh Tanna? Send a correction with the primary source.